Seed IP Law Group is a sponsor of the upcoming "From Preclinical to Clinical: Across Therapeutic Modalities" workshop, taking place at the Seattle Asian Art Museum on November 3 from 11:30 a.m.- 6:00 p.m. PDT. Seed IP Partner Toby Ligon and Associate Kerry Shamnoski are scheduled to attend.

This symposium is for the drug development professional who wants to know more about how therapies of a variety of modalities move from preclinical through to clinical proof of concept. The preclinical data required and nice to have for optimal development as well as clinical design, planning and execution needed for a successful transition into clinical development based on different therapeutic modalities will be discussed. Discussion will include the impact of changes in the guidance around animal usage in preclinical development on clinical planning and dose selection.

The workshop is presented by Pharmaceutical & BioScience Society International (PBSS), a non-profit professional organization of scientists and other professionals in the life science sector, working in diverse organizations such as the biotechnology and pharmaceutical industries, contract research organizations, life science tools suppliers, academia, and government laboratories. PBSS has 20,000+ participants and is active through six member organizations in the San Francisco Bay Area, San Diego, Boston, Seattle, Vancouver, and Korea, some of the largest life science clusters in the World.

Attending from Seed IP:‍

Toby Ligon | Partner, Seed IP Law Group LLP

Kerry Shamnoski | Associate, Seed IP Law Group LLP

***********************************************************************************************************************

"From Preclinical to Clinical: Across Therapeutic Modalities" | Event Description & Agenda

Learn more about Pharmaceutical & BioScience Society International (PBSS).

‍